Effect of Liraglutide on Glycemic Control, Glucagon Secretion and Inflammatory Markers in Adolescents With Type 1 Diabetes Mellitus

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Mar 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Liraglutide (Primary)
Indications Type 1 diabetes mellitus
Focus Therapeutic Use

Most Recent Events

07 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2024.
07 Mar 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.
28 Jul 2021 Status changed from recruiting to active, no longer recruiting.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight